Search results for "rating"

showing 10 items of 2021 documents

Ki-67 Expression as a Factor Predicting Recurrence of Ductal Carcinoma In Situ of the Breast: A Systematic Review and Meta-Analysis

2018

Abstract Background Ki-67 is a marker of proliferating cells; in this meta-analysis we aimed to examine whether Ki-67 expression can predict recurrence rates of breast ductal carcinoma in situ (DCIS). Materials and Methods This systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Eligible articles were sought in MEDLINE up to April 30, 2017. Random effects (DerSimonian–Laird) models were used for the calculation of pooled relative risk (RR) estimates; meta-regression analysis was also performed. Separate analyses were performed according to Ki-67 expression cutoff levels, invasiveness of recurrence,…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyBreast NeoplasmsRisk Assessment03 medical and health sciences0302 clinical medicineBreast cancerInternal medicinemedicineHumansMeta-regressionBreastMastectomybiologybusiness.industryDuctal carcinomaPrognosismedicine.diseaseConfidence intervalCarcinoma Intraductal NoninfiltratingKi-67 Antigen030104 developmental biologyOncology030220 oncology & carcinogenesisRelative riskMeta-analysisKi-67biology.proteinFemaleRadiotherapy AdjuvantNeoplasm Recurrence LocalbusinessCohort studyClinical Breast Cancer
researchProduct

Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer

2021

BackgroundThe prognosis of early breast cancer is linked to clinic-pathological stage and the molecular characteristics of intrinsic tumor cells. In some patients, the amount and quality of tumor-infiltrating immune cells appear to affect long term outcome. We aimed to propose a new tool to estimate immune infiltrate, and link these factors to patient prognosis according to breast cancer molecular subtypes.MethodsWe performed in silico analyses in more than 2800 early breast cancer transcriptomes with corresponding clinical annotations. We first developed a new gene expression deconvolution algorithm that accurately estimates the quantity of immune cell populations (tumor immune contexture,…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMyeloid2435In silicoImmunologyCellbiostatisticsBreast NeoplasmsTranscriptome03 medical and health sciences0302 clinical medicineBreast cancerImmune systemLymphocytes Tumor-InfiltratingInternal medicinemedicineBiomarkers TumorImmunology and Allergytumor microenvironmentHumans1506Stage (cooking)RC254-282Neoplasm StagingPharmacologyClinical/Translational Cancer ImmunotherapyTumor microenvironmentbusiness.industryGene Expression ProfilingNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePrognosisSurvival AnalysisGene Expression Regulation Neoplastic030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesistumor biomarkersMolecular MedicineFemalebusinessAlgorithmsUnsupervised Machine LearningJournal for Immunotherapy of Cancer
researchProduct

Interleukin-6 and Lymphocyte Count Associated and Predicted the Progression of Frailty Syndrome in Prostate Cancer Patients Undergoing Antiandrogen T…

2020

Frailty syndrome is a functional state that includes a loss of ability to react to stressors, and is associated with poor outcomes, morbidity and premature mortality. The first line treatment in many men with prostate cancer (PCa) consists of an androgen-deprivation therapy (ADT) which can promote or favor frailty syndrome and ADT may therefore favor the progression of frailty over time. Among the pathophysiological bases of frailty, the presence of chronic low-grade inflammation has been associated with its adverse outcomes, but longitudinal studies are needed to validate these biomarkers. In this study, we prospectively evaluate frailty syndrome and blood inflammatory markers (IL1-beta, I…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyleukocytesgeriatric assessmentLymphocyteFrailty syndromeInflammationinterleukin-1 betalcsh:RC254-282Article03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicinemedicineInterleukin 6Receiver operating characteristicbiologybusiness.industryinterleukin-6C-reactive proteinlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologymedicine.anatomical_structureOncologyinflammation030220 oncology & carcinogenesisbiology.proteinBiomarker (medicine)biomarkermedicine.symptombusinessCancers
researchProduct

MicroRNA-30a-5pme: a novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma in tissue and urine samples

2020

Abstract Background The rising incidence of renal cell carcinomas (RCC) constitutes a significant challenge owing to risk of overtreatment. Because aberrant microRNA (miR) promoter methylation contributes to cancer development, we investigated whether altered miR-30a-5p expression associates with DNA promoter methylation and evaluated the usefulness as clear cell RCC (ccRCC) diagnostic and prognostic markers. Methods Genome-wide methylome and RNA sequencing data from a set of ccRCC and normal tissue samples from The Cancer Genome Atlas (TCGA) database were integrated to identify candidate CpG loci involved in cancer onset. MiR-30a-5p expression and promoter methylation were quantitatively a…

0301 basic medicineOncologyClear cell renal cell carcinomaCancer Researchmedicine.medical_specialty610Urinelcsh:RC254-28203 medical and health sciences0302 clinical medicineInternal medicinemicroRNADiagnosisMedicineDNA methylationReceiver operating characteristicmicroRNAbusiness.industryResearchBiomarkermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisLog-rank testClear cell renal cell carcinoma030104 developmental biologyOncologyCpG site030220 oncology & carcinogenesisDNA methylationbusinessClear cellJournal of Experimental & Clinical Cancer Research : CR
researchProduct

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

2017

IF 6.029; International audience; BackgroundThe prognostic value of lymphocyte infiltration (LI) of colorectal carcinoma (CC) has been demonstrated by several groups. However, no validated test is currently available for clinical practice. We previously described an automated and reproducible method for testing LI and aimed to validate it for clinical use.Patients and methodsAccording to National Institutes of Health criteria, we designed a prospective validation of this biomarker in patients included in the PETACC8 phase III study. Primary objective was to compare percentage of patients alive and without recurrence at 2 years in patients with high versus low LI (#NCT02364024). Associations…

0301 basic medicineOncologyMaleCancer ResearchOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentMedizinLeucovorinProspective cohort study[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineFOLFOXOrganoplatinum Compounds/therapeutic useAntineoplastic Combined Chemotherapy ProtocolstudyLymphocytesProspective StudiesProspective cohort studyLeucovorin/therapeutic useMiddle AgedPrognosis3. Good healthColorectal carcinomaOncologyFluorouracil030220 oncology & carcinogenesisPredictive value of testsColonic NeoplasmsBiomarker (medicine)Lymphocytes/pathologyFemaleFluorouracilAdjuvantmedicine.drugAdultmedicine.medical_specialty[SDV.CAN]Life Sciences [q-bio]/CancerFluorouracil/therapeutic useBiomarkers Tumor/analysis03 medical and health sciencesLymphocytes Tumor-InfiltratingPredictive Value of TestsBiomarker; Colorectal carcinoma; Immune response; Prospective cohort study; Oncology; Cancer ResearchInternal medicinemedicineBiomarkers TumorHumansImmune responseSurvival analysisAgedbusiness.industryBiomarkermedicine.diseaseSurvival AnalysisSurgery030104 developmental biologyProspective cohort&nbspMultivariate AnalysisColonic Neoplasms/diagnosisAntineoplastic Combined Chemotherapy Protocols/therapeutic usebusiness
researchProduct

Identification of fatal outcome in a childhood nasopharyngeal carcinoma patient by protein expression profiling.

2017

Nasopharyngeal carcinoma (NPC) is a rare disease in children with good prognosis and high cure rate. Nevertheless, certain patients have an unfavorable prognosis due to development of refractory NPC that is unresponsive to any therapeutic strategies. The current study studies a case of a 17 years-old female with non-keratinizing NPC type IIb (T2N0M0), who passed away as a consequence of resistance to chemo-, radio- and β-interferon therapy, and to an allogenic stem cell transplantation. In order to identify factors that lead to treatment failure and fatal outcome, immunohistochemical analyses of different tumor biomarkers and hierarchical cluster analysis were performed and compared with th…

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_specialtyHerpesvirus 4 HumanAdolescentBiologymedicine.disease_causeVirusViral Matrix Proteins03 medical and health sciencesImmunocompromised Host0302 clinical medicineLymphocytes Tumor-InfiltratingInternal medicineotorhinolaryngologic diseasesmedicineBiomarkers TumorHumansProspective StudiesChildImmunodeficiencyNasopharyngeal CarcinomaTumor-infiltrating lymphocytesGene Expression ProfilingVaricella zoster virusCancermedicine.diseasePrognosisImmunohistochemistryTransplantationstomatognathic diseases030104 developmental biologyHerpes simplex virusOncologyNasopharyngeal carcinomaDrug Resistance Neoplasm030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalStem Cell TransplantationInternational journal of oncology
researchProduct

A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for…

2020

AIMS Studies in various cancer types have demonstrated discordance between results from different programmed death-ligand 1 (PD-L1) assays. Here, we compare the reproducibility and analytical concordance of four clinically developed assays for assessing PD-L1-positivity in tumour-infiltrating immune cells in the tumour area (PD-L1-IC-positivity) in triple-negative breast cancer (TNBC). METHODS AND RESULTS Primary TNBC resection specimens (n = 30) were selected based on their PD-L1-IC-positivity per VENTANA SP142 ( 5%: eight cases). Serial histological sections were stained for PD-L1 using VENTANA SP142, VENTANA SP263, DAKO 22C3 and DAKO 28-8. PD-L1-IC-positivity and tumour cell expression (…

0301 basic medicineOncologyMalemedicine.medical_specialtyHistologyConcordanceTriple Negative Breast NeoplasmsB7-H1 AntigenPathology and Forensic MedicineCohort Studies03 medical and health sciences0302 clinical medicineBreast cancerLymphocytes Tumor-InfiltratingInternal medicinemedicineBiomarkers TumorHumansTriple-negative breast cancerAgedReproducibilityWhole Genome Sequencingbusiness.industryCancerHigh-Throughput Nucleotide SequencingReproducibility of ResultsGeneral MedicineMiddle Agedmedicine.diseaseImmunohistochemistryddc:030104 developmental biology030220 oncology & carcinogenesisMutationComparison studyImmunohistochemistryFemaleNeoplasm GradingbusinessProgrammed deathHistopathologyReferences
researchProduct

The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis

2018

AbstractThis pooled analysis aims at evaluating the diagnostic accuracy of circulating tumor (ct) DNA for the detection of EGFR-T790M mutation in NSCLC patients who progressed after EGFR-TKIs. Data from all published studies, reporting both sensitivity and specificity of plasma-based EGFR-T790M mutation testing by ctDNA were collected by searching in PubMed, Cochrane Library, American Society of Clinical Oncology, European Society of Medical Oncology and World Conference of Lung Cancer meeting proceedings. A total of twenty-one studies, with 1639 patients, were eligible. The pooled sensitivity of ctDNA analysis was 0.67 (95% CI: 0.64–0.70) and the pooled specificity was 0.80 (95% CI: 0.77–0…

0301 basic medicineOncologyMalemedicine.medical_specialtyLung NeoplasmsctDNA EGFR-T790M NSCLCMutation Missenselcsh:MedicineCochrane LibraryLikelihood ratios in diagnostic testingArticleCirculating Tumor DNA03 medical and health sciencesAmino Acid Substitution; ErbB Receptors; Female; Humans; Male; Predictive Value of Tests; Carcinoma Non-Small-Cell Lung; Circulating Tumor DNA; Lung Neoplasms; Mutation Missense; Neoplasm Proteins0302 clinical medicinePredictive Value of TestsInternal medicineCarcinoma Non-Small-Cell LungmedicineHumansLung cancerNon-Small-Cell Lunglcsh:ScienceMultidisciplinaryReceiver operating characteristicbusiness.industryCarcinomalcsh:RArea under the curvemedicine.diseasePublisher CorrectionNeoplasm ProteinsErbB Receptors030104 developmental biologyAmino Acid Substitution030220 oncology & carcinogenesisPredictive value of testsMeta-analysisMutationDiagnostic odds ratioFemalelcsh:QMissensebusinessScientific Reports
researchProduct

Prognostic Value of Immune Environment Analysis in Small Bowel Adenocarcinomas with Verified Mutational Landscape and Predisposing Conditions

2020

Background: Small bowel adenocarcinoma (SBA) is a rare yet insidious cancer with poor survival. The abundance of tumour-infiltrating lymphocytes is associated with improved survival, but the role of the programmed death-1/programmed death ligand-1 (PD-1/PD-L1) pathway in tumour escape is controversial. We evaluated immune cell infiltration, PD1/PD-L1 expression and their prognostic value in a series of SBAs with previously verified predisposing conditions and exome-wide somatic mutation characterization. Methods: Formalin-fixed paraffin-embedded tissue sections stained for CD3, CD8, PD-L1 and PD-1 were analysed from 94 SBAs. An immune cell score (ICS) was formed from the amount of the CD3 a…

0301 basic medicineOncologyPD-L1Cancer Researchmedicine.medical_specialtyadenokarsinoomabiomarkkeritsuolistosyövätlcsh:RC254-282ArticlePathogenesis03 medical and health sciencestumour infiltrating lymphocytesohjelmoitunut solukuolema0302 clinical medicineGermline mutationImmune systemPD-L1Internal medicinesmall bowelPD-1medicineStage (cooking)adenocarcinomabiologybusiness.industryCancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease3. Good health030104 developmental biologyOncologyimmuunijärjestelmä030220 oncology & carcinogenesisbiology.proteinAdenocarcinomaohutsuolisyöpätauditproteiinitlymfosyytitbusinessCD8
researchProduct

Liquid biopsy as surrogate for tissue for molecular profiling in pancreatic cancer: A meta-analysis towards precision medicine

2019

Liquid biopsy (LB) is a non-invasive approach representing a promising tool for new precision medicine strategies for cancer treatment. However, a comprehensive analysis of its reliability for pancreatic cancer (PC) is lacking. To this aim, we performed the first meta-analysis on this topic. We calculated the pooled sensitivity, specificity, positive (LR+) and negative (LR-) likelihood ratio, and diagnostic odds ratio (DOR). A summary receiver operating characteristic curve (SROC) and area under curve (AUC) were used to evaluate the overall accuracy. We finally assessed the concordance rate of all mutations detected by multi-genes panels. Fourteen eligible studies involving 369 patients wer…

0301 basic medicineOncologymedicine.medical_specialtyCancer ResearchConcordanceprecision medicinepancreatic cancerReviewlcsh:RC254-282Circulating tumor cells (CTC)03 medical and health sciences0302 clinical medicineInternal medicinePancreatic cancermedicineLiquid biopsycfDNALiquid biopsyReceiver operating characteristicliquid biopsybusiness.industryCfDNAPrecision medicinePancreatic cancerPrecision medicinemedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthCancer treatment030104 developmental biologyOncologycirculating tumor cells (CTC)030220 oncology & carcinogenesisMeta-analysisDiagnostic odds ratiobusinesscfDNA; circulating tumor cells (CTC); liquid biopsy; pancreatic cancer; precision medicine
researchProduct